News Releases 2014
Faron has received positive information on its pending patent applications related to serum CD73 measurements in patients suffering for ischemic conditions.
The licensing Partner for Traumakine in Japan, Maruishi Pharmaceutical Co., Ltd. has informed Faron that their clinical application to Japanese regulatory Agency (PMDA) has been accepted and the phase II clinical trial has been initiated accordingly.
Faron scientific network publishes an important article on Clever-1 mechanism for tumour growth inhibition
Turku – Finland, October 16, 2014. The Faron scientific network has informed the company that the Clinical Cancer Research, a highly ranked journal of the American Cancer Research Organization, has accepted for publication their article on the mechanism of action of the Clever-1 molecule to suppress tumor growth and metastasis. The Karikoski et al. (2014) article is already available as an on-line version at www.clincancerres.aacrjournals.org.
Turku – Finland, February 4, 2014. Faron informed today that the printed version of the article by Bellingan et al., which became available as an online version on December 23rd, 2013, has been now published in the February issue of the The Lancet Respiratory Medicine. The article is attached to this press release for interested readers and describes the detailed data of those significant results obtained with FP-1201 treatment of ARDS (acute respiratory distress syndrome).
Turku – Finland, January 2, 2014. Together with its network of scientists and clinicians Faron Pharmaceuticals Ltd. has developed a promising new treatment for life threatening acute respiratory distress syndrome (ARDS). The FPCLI001 study, which reduced the odds of all cause mortality by more than 80 percent among the ARDS patients, has been published online in the distinguished medical journal: The Lancet Respiratory Medicine.